Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2023-10 · 15 (4)
DOI: 10.1002/dad2.12508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, online erschienen am 04.12.2023. Verfasst von Ivonne Suridjan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Roche Diagnostics International Ltd Rotkreuz Switzerland. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION Disease‐modifying therapies (DMTs) for Alzheimer's disease (AD) will increase diagnostic demand. A non‐invasive blood‐based biomarker (BBBM) test for detection of amyloid‐β pathology may reduce diagnostic barriers and facilitate DMT initiation. OBJECTIVE To explore heterogeneity in AD care pathways and potential role of BBBM tests. METHODS Survey of 213 healthcare professionals/payers in US/China/UK/Germany/Spain/France and two advisory boards (US/Europe). RESULTS Current diagnostic pathways are heterogeneous, meaning many AD patients are missed while low‐risk patients undergo unnecessary procedures. Confirmatory amyloid testing (cerebrospinal fluid biomarkers/positron emission tomography) is utilized in few patients, resulting in diagnostic/treatment delays. A high negative‐predictive‐value test could streamline the diagnostic pathway by reducing unnecessary procedures in low‐risk patients; supporting confirmatory testing where needed. Imminent approval of DMTs will increase need for fast and reliable AD diagnostic tests. DISCUSSION An easy‐to‐use, accurate, non‐invasive BBBM test for amyloid pathology could guide diagnostic procedures or referral, streamlining early diagnosis and DMT initiation. Highlights This study explored AD care pathways and how BBBM may meet diagnostic demands Current diagnostic pathways are heterogeneous, with country and setting variations Many AD patients are missed, while low‐risk patients undergo unnecessary procedures An easy‐to‐use, accurate, non‐invasive BBBM test for amyloid pathology is needed This test could streamline early diagnosis of amyloid pathology and DMT initiation
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Roche Diagnostics International Ltd Rotkreuz Switzerland.
- Alzheimer Center Amsterdam Neurology, Epidemiology and Data Science, Vrije Universiteit Amsterdam Amsterdam UMC location VUmc Amsterdam The Netherlands.
- Amsterdam Neuroscience Neurodegeneration Amsterdam The Netherlands.
- Memory Clinic University Department of Geriatric Medicine FELIX PLATTER Basel Switzerland.
- General Practice, South West London CCG London UK.
- Department of Family Medicine and Community Health UMass Chan Medical School, North Worcester Massachusetts USA.
Zitieren
APA
Suridjan, I., van der Flier, W. M., Monsch, A. U., Burnie, N., Baldor, R., Sabbagh, M., Vilaseca, J., Cai, D., Carboni, M., & Lah, J. J. (2023). Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 15(4). https://doi.org/10.1002/dad2.12508
Vancouver
Suridjan I, van der Flier WM, Monsch AU, Burnie N, Baldor R, Sabbagh M, et al. Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2023;15(4). doi:10.1002/dad2.12508
BibTeX
@article{Suridjan2023,
author = {Suridjan, Ivonne and van der Flier, Wiesje M and Monsch, Andreas U and Burnie, Nerida and Baldor, Robert and Sabbagh, Marwan and Vilaseca, Josep and Cai, Dongming and Carboni, Margherita and Lah, James J},
title = {Blood‐based biomarkers in Alzheimer's disease: Future directions for implementation},
journal = {Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring},
year = {2023},
volume = {15},
number = {4},
doi = {10.1002/dad2.12508}
}
EUVIMED